In concordance with our findings, a recent study showed that CXCR2 inhibition was found to augment programed cell death 1 (PD-1) inhibition in pancreatic cancer (Steele et al., 2016). This evidence concerns the gene CXCR2 and familial pancreatic carcinoma.